Hanmi Pharm announced on the 4th that it has launched’Rosujet’, a new complex drug for dyslipidemia, through its partner, Organon & Co., a subsidiary of MSD in Mexico, one of the largest pharmaceutical markets in Latin America. The product name of Rosujet distributed in Mexico is’NAXZALLA’ and is sold in three doses (10/5mg, 10/10mg, and 10/20mg).
Rosujet is a combination drug that combines two ingredients, rosuvastatin and ezetimibe, that treat dyslipidemia. It is characterized by effectively lowering LDL-C in blood by double inhibition of cholesterol synthesis and absorption in the liver and small intestine. The robust product power of the combination of rosuvastatin and ezetimibe is known to the world, with 4 papers registered in SCI-level international academic journals. Rosujet has grown rapidly by more than 20% every year in the domestic dyslipidemia market. Last year, it achieved sales of 99.1 billion won (based on UBIST), ranking first in domestically developed prescription drugs.
“Rosujet is a complex new drug that achieved No. 1 in domestic prescription sales among single prescription drugs developed by Korean pharmaceutical companies,” said Hanmi Pharm’s CEO Jongsoo Woo. “We will do our best to ensure that our achievements in Korea can be continued around the world, including Central and South America. “He said.
Initially, Hanmi Pharm signed an export contract with MSD of the US to export Rosujet to 23 countries in the world, but recently, the contract subject changed as MSD established a new corporation,’Organon,’ which will be in charge of certain specialty drug business such as cardiovascular system. Organon obtained the marketing license of’NAXZALLA’ from the Mexican Pharmaceutical Authority (COFEPRIS) in July of last year.
The Mexican pharmaceutical market is growing by more than 10% each year and is worth 15 trillion won per year, making it the second largest market in Latin America after Brazil. In particular, the obesity rate of Mexicans is second in the world after the United States, and the incidence of cardio-cerebrovascular metabolic diseases such as dyslipidemia is high, and the related drug market is rapidly growing.
Organon is engaged in active marketing activities of NAXZALLA in Mexico. In the recent NAXZALLA online symposium for Mexican medical staff, local internal medical staff received a great deal of participation and response. In addition to the export countries signed with Organon, Hanmi Pharm is doing its best to launch Rosujet in a number of regions such as Argentina, Asia and Africa.
Reporter Se-ra Kim, Consumer Economic Daily